REC-1170204 / Recursion Pharma - LARVOL DELTA

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire) - "RBM39 HR-Proficient Ovarian Cancers and Other Solid Tumors: RBM39 is a novel CDK12-adjacent target identified by the Recursion OS. We intend to position our lead candidate as a single agent for the potential treatment of HR-proficient ovarian cancers and other HR-proficient solid tumors....We are advancing our lead candidate through IND-enabling studies with IND submission expected in H2 2024."

IND • Ovarian Cancer

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results (GlobeNewswire) - "Pipeline:...RBM39 HR-Proficient Ovarian Cancer: RBM39 (previously identified as Target Gamma) is a novel CDK12-adjacent target identified by the Recursion OS. We believe we can modulate this target to produce a therapeutic effect in HR-proficient ovarian cancer and potentially in other tumor types. This program is in the preclinical stage and IND-enabling studies are progressing."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor